Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FAHED BITAR

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1174728612
CMS profile
325557
Location
COVINA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$18,180.23

187 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FAHED BITAR

NPI 1174728612 · CMS profile ID 325557

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

COVINA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174728612?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FAHED BITAR, NPI 1174728612, CMS profile ID 325557. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174728612?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). FAHED BITAR, NPI 1174728612, CMS profile ID 325557. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174728612?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
FAHED BITAR, NPI 1174728612, CMS profile ID 325557, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 187 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1174728612?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

187 matching records · $18,180.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 187 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 187.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $5.9509/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926509 CMS
AstraZeneca Pharmaceuticals LP $11.5109/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685593279 CMS
Regeneron Healthcare Solutions, Inc. $20.7509/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673344931 CMS
Novartis Pharmaceuticals Corporation $14.8109/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926505 CMS
Amgen Inc. $22.6309/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663235191 CMS
Kowa Pharmaceuticals America, Inc. $15.1609/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630256467 CMS
PFIZER INC. $21.1009/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672923833 CMS
PFIZER INC. $10.1309/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672990431 CMS
Teleflex LLC $17.8909/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688677007 CMS
ABIOMED $13.0409/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676721507 CMS
Abbott Laboratories $24.2909/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664512507 CMS
Novartis Pharmaceuticals Corporation $5.9708/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926503 CMS
SANOFI-AVENTIS U.S. LLC $21.1508/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694149369 CMS
Boston Scientific Corporation $22.5708/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662749383 CMS
ABIOMED $34.6508/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676721495 CMS
Boston Scientific Corporation $19.3708/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662749377 CMS
Medtronic Vascular, Inc. $4.2708/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677012971 CMS
E.R. Squibb & Sons, L.L.C. $500.0008/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651243469 CMS
Janssen Pharmaceuticals, Inc $22.5008/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658335441 CMS
Medtronic Vascular, Inc. $39.1208/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 677012985 CMS
Novartis Pharmaceuticals Corporation $19.2308/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926491 CMS
E.R. Squibb & Sons, L.L.C. $13.1908/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651243347 CMS
Novartis Pharmaceuticals Corporation $6.1208/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926501 CMS
Amgen Inc. $14.5708/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663235189 CMS
AstraZeneca Pharmaceuticals LP $11.5508/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685299873 CMS
BIOTRONIK INC. $23.9308/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701545405 CMS
Teleflex LLC $29.1608/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688677009 CMS
ABIOMED $19.8108/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676721345 CMS
PFIZER INC. $10.5107/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672394489 CMS
SANOFI-AVENTIS U.S. LLC $21.7807/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694087605 CMS
Novartis Pharmaceuticals Corporation $6.0107/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926499 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $11.9207/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625135515 CMS
Amarin Pharma Inc. $20.0007/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699184649 CMS
Amarin Pharma Inc. $116.2907/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699187889 CMS
Boston Scientific Corporation $17.8807/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662749371 CMS
Novartis Pharmaceuticals Corporation $18.5207/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926497 CMS
SANOFI-AVENTIS U.S. LLC $21.7407/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694112693 CMS
Amgen Inc. $16.1907/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663235185 CMS
Novartis Pharmaceuticals Corporation $5.8807/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926495 CMS
Amgen Inc. $27.0107/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663235181 CMS
Amgen Inc. $25.8207/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663235179 CMS
Novartis Pharmaceuticals Corporation $3.7107/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926493 CMS
Abbott Laboratories $21.6507/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664523375 CMS
ABIOMED $27.8007/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676721335 CMS
Novartis Pharmaceuticals Corporation $36.1407/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926479 CMS
Novartis Pharmaceuticals Corporation $5.8907/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926489 CMS
Amgen Inc. $22.0007/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663235175 CMS
Boston Scientific Corporation $22.5807/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662749387 CMS
Abbott Laboratories $23.8707/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 664560109 CMS
Novartis Pharmaceuticals Corporation $5.8207/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658926487 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,180.23 187
PY2020 $5,885.67 114
PY2021 $6,507.66 180
PY2022 $2,318.15 117
PY2023 $2,630.89 122
PY2024 $2,542.79 115
PY2025 $3,077.40 127

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,372,659.41 119
PY2024 Recipient $88,784.30 8
PY2024 Principal investigator $2,456,127.72 65
PY2023 Recipient $1,782.00 4
PY2023 Principal investigator $1,385,141.16 67
PY2022 Recipient $146.00 2
PY2022 Principal investigator $1,147,808.22 159
PY2021 Recipient $117,186.47 2
PY2021 Principal investigator $1,046,387.72 200
PY2020 Recipient $196.80 1
PY2020 Principal investigator $840,011.26 516
PY2019 Recipient $22,855.79 2
PY2019 Principal investigator $568,169.67 95

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

119 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,465.01 12/31/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc.
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920322
Principal investigator 1 Boehringer Ingelheim International GmbH $1,775.00 12/12/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754532
Principal investigator 1 Boehringer Ingelheim International GmbH $1,125.00 12/03/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754530
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 12/03/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220998016
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,149.24 11/24/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) No dispute reported 06/30/2026 1190309568
Principal investigator 1 Boehringer Ingelheim International GmbH $3,828.00 11/19/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754518
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 11/19/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754520
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 11/19/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754522
Principal investigator 1 Boehringer Ingelheim International GmbH $2,470.00 11/19/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754524
Principal investigator 1 Boehringer Ingelheim International GmbH $3,623.00 11/19/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754526
Principal investigator 1 Boehringer Ingelheim International GmbH $171.00 11/19/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754528
Principal investigator 1 Novartis Pharmaceuticals Corporation $20.16 11/15/2025 Non-covered Recipient Entity
FOOTHILL CARDIOLOGY
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190308296
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,500.00 11/12/2025 Non-covered Recipient Entity
STONY BROOK INTERNISTS
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190313415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,143.60 11/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513627
Principal investigator 1 Amgen Inc. $289.18 10/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS - COVINA
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246651115
Principal investigator 1 Boehringer Ingelheim International GmbH $3,828.00 10/20/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754506
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 10/20/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754508
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 10/20/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754510
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,662.32 10/20/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS COVINA
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) No dispute reported 06/30/2026 1190310178
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 10/15/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220998014
Principal investigator 1 Amgen Inc. $1,509.32 10/08/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS - COVINA
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246651120
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 10/02/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754494
Principal investigator 1 Boehringer Ingelheim International GmbH $14,000.00 10/02/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754496
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/02/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754498
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 10/02/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754500
Principal investigator 1 Boehringer Ingelheim International GmbH $2,618.00 10/02/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754502
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/02/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754504
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/02/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754512
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/02/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754514
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 10/02/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754516
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 09/10/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $240.00 09/05/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513542
Principal investigator 1 Amgen Inc. $65,146.93 08/29/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS, INC.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246651152
Principal investigator 1 ModernaTX, Inc. $39.52 08/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $119.00 08/27/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513538
Principal investigator 1 Boehringer Ingelheim International GmbH $599.40 08/26/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754492
Principal investigator 1 Eli Lilly and Company $39,240.00 08/26/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF LY3549492 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS 55 TO 80 YEARS OF AGE AND BMI WITHIN 22 TO 25 KG/M2 No dispute reported 06/30/2026 1187882704
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,077.60 08/20/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513500
Principal investigator 1 Merck Sharp & Dohme LLC $17,907.40 08/14/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc.
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920320
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 08/06/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513546
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 07/30/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754488
Principal investigator 1 Amgen Inc. $35,816.75 07/29/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS, INC.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246651138
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 07/28/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754490
Principal investigator 1 AstraZeneca UK Limited $19,400.00 07/21/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185553789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,155.20 07/16/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513496
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,454.28 07/15/2025 Non-covered Recipient Entity
STONY BROOK INTERNISTS
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190313417
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,539.68 07/15/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190313611
Principal investigator 1 ModernaTX, Inc. $830.13 06/26/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003761
Principal investigator 1 ModernaTX, Inc. $8,791.86 06/18/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003747
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,500.00 06/02/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] No dispute reported 06/30/2026 1190313603
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 05/28/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220998012
Principal investigator 1 ModernaTX, Inc. $6,935.76 05/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003757
Principal investigator 1 ModernaTX, Inc. $22,607.64 05/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003759
Principal investigator 1 ModernaTX, Inc. $4,383.00 05/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003765
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,274.64 05/28/2025 Non-covered Recipient Entity
FOOTHILL CARDIOLOGY
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] No dispute reported 06/30/2026 1190308292
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 05/27/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754482
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 05/27/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754484
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 05/27/2025 Non-covered Recipient Entity
Flourish Research
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220754486
Principal investigator 1 Eli Lilly and Company $312,405.00 05/27/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 No dispute reported 06/30/2026 1187882548
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,980.25 05/21/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513464
Principal investigator 1 ModernaTX, Inc. $830.13 05/15/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003793
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,516.36 05/15/2025 Non-covered Recipient Entity
FOOTHILL CARDIOLOGY
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] No dispute reported 06/30/2026 1190308294
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 05/07/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513472
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 05/02/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513437
Principal investigator 1 Eli Lilly and Company $165.00 04/30/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187891980
Principal investigator 1 ModernaTX, Inc. $2,922.00 04/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003751
Principal investigator 1 ModernaTX, Inc. $2,015.52 04/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003767
Principal investigator 1 ModernaTX, Inc. $418.66 04/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003769
Principal investigator 1 ModernaTX, Inc. $7,074.08 04/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003779
Principal investigator 1 ModernaTX, Inc. $4,383.00 04/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $338.80 04/18/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513491
Principal investigator 1 Eli Lilly and Company $9,193.51 04/14/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WITH HYPERTENSION AND OBESITY OR OVERWEIGHT: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS (ATTAIN-HYPERTENSION). ISAS-GZL1;GZL2 No dispute reported 06/30/2026 1187892610
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,293.75 04/09/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513484
Principal investigator 1 Alnylam Pharmaceuticals Inc. $238.00 04/04/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513440
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,309.00 04/04/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $60.00 04/04/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513449
Principal investigator 1 ModernaTX, Inc. $10,466.50 03/24/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003743
Principal investigator 1 ModernaTX, Inc. $8,259.68 03/24/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003749
Principal investigator 1 ModernaTX, Inc. $16,071.00 03/24/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003755
Principal investigator 1 ModernaTX, Inc. $2,082.20 03/24/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $119.00 03/19/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513382
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 03/03/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513342
Principal investigator 1 ModernaTX, Inc. $2,082.20 02/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003745
Principal investigator 1 ModernaTX, Inc. $9,465.04 02/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003753
Principal investigator 1 ModernaTX, Inc. $14,610.00 02/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003763
Principal investigator 1 ModernaTX, Inc. $13,815.78 02/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003771
Principal investigator 1 Novartis Pharmaceuticals Corporation $55,357.28 02/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190313597
Principal investigator 1 Eli Lilly and Company $1,775.80 02/25/2025 Non-covered Recipient Entity
MEHRDAD KEVIN ARIANI MD
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187884498
Principal investigator 1 Eli Lilly and Company $4,360.13 02/25/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187891978
Principal investigator 1 Eli Lilly and Company $109.80 02/25/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187893536
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 02/21/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513358
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,800.00 02/12/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $60.00 02/12/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513374
Principal investigator 1 Novartis Pharmaceuticals Corporation $49,509.39 02/04/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190313609
Principal investigator 1 Novartis Pharmaceuticals Corporation $401,701.45 02/03/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS COVINA
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease No dispute reported 06/30/2026 1190310174
Principal investigator 1 Eli Lilly and Company $405.00 01/31/2025 Non-covered Recipient Entity
MEHRDAD KEVIN ARIANI MD
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187885718
Principal investigator 1 Eli Lilly and Company $2,781.04 01/31/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187892014
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,358.01 01/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190313605
Principal investigator 1 ModernaTX, Inc. $26,027.50 01/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003777
Principal investigator 1 ModernaTX, Inc. $9,702.16 01/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003781
Principal investigator 1 ModernaTX, Inc. $418.66 01/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003785
Principal investigator 1 ModernaTX, Inc. $16,071.00 01/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003789
Principal investigator 1 Eli Lilly and Company $24.90 01/22/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187892016
Principal investigator 1 ModernaTX, Inc. $436.80 01/22/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003773
Principal investigator 1 Eli Lilly and Company $160,197.00 01/21/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187891612
Principal investigator 1 Eli Lilly and Company $162,260.00 01/21/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187892600
Principal investigator 1 Eli Lilly and Company $56,867.00 01/17/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187890986
Principal investigator 1 ModernaTX, Inc. $7,471.17 01/16/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003787
Principal investigator 1 ModernaTX, Inc. $436.80 01/16/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003791
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,971.20 01/15/2025 Non-covered Recipient Entity
FOOTHILL CARDIOLOGY
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190308298
Principal investigator 1 Novartis Pharmaceuticals Corporation $95,120.66 01/15/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS COVINA
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190310176
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,073.64 01/09/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS COVINA
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190310180
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 01/08/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513319
Principal investigator 1 Alnylam Pharmaceuticals Inc. $500.00 01/08/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,925.80 01/08/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,938.40 01/08/2025 Non-covered Recipient Entity
Valley Clinical Trials, Inc - Covina - Flourish - PPDS
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215513428
Principal investigator 1 Eli Lilly and Company $333,614.00 01/07/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187882700
Principal investigator 1 Eli Lilly and Company $168.00 01/06/2025 Non-covered Recipient Entity
CALIFORNIA ALLERGY AND ASTHMA MEDICAL GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187876573
Principal investigator 1 Eli Lilly and Company $125,829.00 01/06/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187892772